Skip to main content
. 2018 Mar 9;97(10):e0097. doi: 10.1097/MD.0000000000010097

Figure 3.

Figure 3

Forest plots showing hazard ratio (HR) for progression-free survival (PFS; A–B), overall survival (OS; C–D), and overall response rate (ORR; E–F) comparing FOLOFX plus anti-EGFR antibody with FOLFOX for the subgroups of left-sided and right-sided colorectal cancer.